Do you want to read an article? Please log in or register.
Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters: An open-label extension trial
Epilepsy
RECOMMENDED
Related content
Epilepsy
Final results from a Phase 3, long-term, open-label, repeat-dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy
Epilepsia
Wheless JW, Miller I, Hogan RE, Dlugos D, Biton V, Cascino GD, Sperling MR, Liow K, Vazquez B, Segal EB, Tarquinio D, Mauney W, Desai J, Rabinowicz AL, Carrazana E, DIAZ.001.05 Study Group.
doi: 10.1111/epi.17041
Epilepsy
Safety and efficacy of midazolam nasal spray for the treatment of intermittent bouts of increased seizure activity in the epilepsy monitoring unit: A double-blind, randomized, placebo-controlled trial
Epilepsia
Spencer DC, Sinha SR, Choi EJ, Cleveland JM, King A, Meng TC, Pullman WE, Sequeira DJ, Van Ess PJ, Wheless JW
doi: 10.1111/epi.16704
Epilepsy
Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307
Epilepsia.
Krauss GL, Perucca E, Kwan P, Ben-Menachem E, Wang XF, Shih JJ, Patten A, Yang H, Williams B, Laurenza A
doi: 10.1111/epi.14044.
Anxiety and Depression
Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2)
J Clin Psychiatry.
Wajs E, Aluisio L, Holder R, Daly EJ, Lane R, Lim P, George JE, Morrison RL, Sanacora G, Young AH, Kasper S, Sulaiman AH, Li CT, Paik JW, Manji H, Hough D, Grunfeld J, Jeon HJ, Wilkinson ST, Drevets WC, Singh JB
doi: 10.4088/JCP.19m12891.
Epilepsy
Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial
Epilepsia.
Devinsky O, Nabbout R, Miller I, Laux L, Zolnowska M, Wright S, Roberts C
doi: 10.1111/epi.
Epilepsy
Long-term safety, efficacy, and quality of life outcomes with adjunctive brivaracetam treatment at individualized doses in patients with epilepsy: An up to 11-year, open-label, follow-up trial
★ 1
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Epilepsia.
O'Brien TJ, Borghs S, He QJ, Schulz AL, Yates S, Biton V
doi: 10.1111/epi.16484.
Epilepsy
Long-term safety and efficacy of add-on cannabidiol in patients with Lennox-Gastaut syndrome: Results of a long-term open-label extension trial
Epilepsia
Patel AD, Mazurkiewicz-Bełdzińska M, Chin RF, Gil-Nagel A, Gunning B, Halford JJ, Mitchell W, Scott Perry M, Thiele EA, Weinstock A, Dunayevich E, Checketts D, Devinsky O
doi: 10.1111/epi.17000
Epilepsy
Assessment of the long-term efficacy and safety of adjunctive perampanel in tonic-clonic seizures: Analysis of four open-label extension studies
Epilepsia.
Rektor I, Krauss GL, Inoue Y, Kaneko S, Williams B, Patten A, Malhotra M, Laurenza A, Wechsler RT
doi: 10.1111/epi.16573.
Epilepsy
Evaluation of diazepam nasal spray in patients with epilepsy concomitantly using maintenance benzodiazepines: An interim subgroup analysis from a phase 3, long-term, open-label safety study
Epilepsia
Segal EB, Tarquinio D, Miller I, Wheless JW, Dlugos D, Biton V, Cascino GD, Desai J, Hogan RE, Liow K, Sperling MR, Vazquez B, Cook DF, Rabinowicz AL, Carrazana E, DIAZ.001.05 Study Group.
doi: 10.1111/epi.16901